{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:41Z","timestamp":1787956001682,"version":"build-2784847793"},"reference-count":24,"publisher":"BMJ","issue":"11","funder":[{"name":"Cure SMA Canada"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is a neuromuscular disorder that manifests with motor deterioration and respiratory complications. The paradigm of care is shifting as disease-modifying therapies including nusinersen, onasemnogene abeparvovec and risdiplam alter the disease trajectory of SMA. The objective of this study was to explore caregivers\u2019 experiences with disease-modifying therapies for SMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Qualitative study including semistructured interviews with caregivers of children with SMA who received disease-modifying therapies. Interviews were audio recorded, transcribed verbatim, coded and analysed using content analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The Hospital for Sick Children (Toronto, Canada).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen family caregivers of children with SMA type 1 (n=5), type 2 (n=5) and type 3 (n=5) participated. There were two emerging themes and several subthemes (in parentheses): (1) inequities in access to disease-modifying therapies (variable regulatory approvals, prohibitively expensive therapies and insufficient infrastructure) and (2) patient and family experience with disease-modifying therapies (decision making, hope, fear and uncertainty).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The caregiver experience with SMA has been transformed by the advent of disease-modifying therapies. Consistent and predictable access to disease-modifying therapies is a major concern for caregivers of children with SMA but is influenced by regulatory approvals, funding and eligibility criteria that are heterogenous across jurisdictions. Many caregivers described going to great lengths to access therapies, highlighting issues related to justice, such as equity and access. This diverse population reflects contemporary patients and families with SMA; their broad experiences may inform the healthcare delivery of other emerging orphan drugs.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2023-325762","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T17:25:17Z","timestamp":1688750717000},"page":"929-934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: a qualitative study"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-1217","authenticated-orcid":false,"given":"Lena","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djurdja","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Gonorazky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazzah","family":"Ambreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McCradden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2023103003200620000_108.11.929.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"2023103003200620000_108.11.929.2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2278"},{"key":"2023103003200620000_108.11.929.3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"2023103003200620000_108.11.929.4","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000290830.40544.b9"},{"key":"2023103003200620000_108.11.929.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"2023103003200620000_108.11.929.6"},{"key":"2023103003200620000_108.11.929.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2102047"},{"key":"2023103003200620000_108.11.929.8","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41436-020-0890-6","article-title":"Patient and family social media use surrounding a novel treatment for a rare genetic disease: a qualitative interview study","volume":"22","author":"Iyer","year":"2020","journal-title":"Genet Med"},{"key":"2023103003200620000_108.11.929.9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-180330","article-title":"Perspectives on Spinraza (Nusinersen) treatment study: views of individuals and parents of children diagnosed with spinal muscular atrophy","volume":"6","author":"Pacione","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"2023103003200620000_108.11.929.10","doi-asserted-by":"crossref","unstructured":"Kiefer P , Kirschner J , Pechmann A , et al . Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study. Orphanet J Rare Dis 2020;15:194. doi:10.1186\/s13023-020-01477-7","DOI":"10.1186\/s13023-020-01477-7"},{"key":"2023103003200620000_108.11.929.11","doi-asserted-by":"crossref","unstructured":"Pasquini TLS , Goff SL , Whitehill JM . Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents\u2019 experiences. Orphanet J Rare Dis 2021;16:313. doi:10.1186\/s13023-021-01943-w","DOI":"10.1186\/s13023-021-01943-w"},{"key":"2023103003200620000_108.11.929.12","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2023103003200620000_108.11.929.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0260-6917(96)80115-8"},{"key":"2023103003200620000_108.11.929.14","unstructured":"Biogen . New data at cure SMA 2021 highlight the long-term efficacy of SPINRAZA\u00ae (Nusinersen) and Biogen\u2019s commitment to innovation in SMA therapy. 2021. Available: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-data-cure-sma-2021-highlight-long-term-efficacy-spinrazar"},{"key":"2023103003200620000_108.11.929.15","unstructured":"SMA NBS Alliance . Status of spinal muscular atrophy newborn screening in Europe. 2022. Available: https:\/\/www.sma-screening-alliance.org\/map\/"},{"key":"2023103003200620000_108.11.929.16","unstructured":"Novartis . Newborn screening for spinal muscular atrophy (SMA). 2022. Available: https:\/\/www.novartis.com\/about\/innovative-medicines\/novartis-pharmaceuticals\/novartis-gene-therapies\/newborn-screening-spinal-muscular-atrophy-sma"},{"key":"2023103003200620000_108.11.929.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.03.007"},{"key":"2023103003200620000_108.11.929.18","doi-asserted-by":"crossref","unstructured":"Fortunato F , Rossi R , Falzarano MS , et al . Innovative therapeutic approaches for Duchenne muscular dystrophy. J Clin Med 2021;10:820. doi:10.3390\/jcm10040820","DOI":"10.3390\/jcm10040820"},{"key":"2023103003200620000_108.11.929.19","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38418"},{"key":"2023103003200620000_108.11.929.20","doi-asserted-by":"crossref","unstructured":"Daniels N . Just health: meeting health needs fairly \/ Norman Daniels. Cambridge: Cambridge University Press, 2007. doi:10.1017\/CBO9780511809514","DOI":"10.1017\/CBO9780511809514"},{"key":"2023103003200620000_108.11.929.21","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170195"},{"key":"2023103003200620000_108.11.929.22","doi-asserted-by":"crossref","unstructured":"Rawson NS , Adams J . Access to new drugs for rare disorders in Canada. CMAJ 2018;190:E840. doi:10.1503\/cmaj.69340","DOI":"10.1503\/cmaj.69340"},{"key":"2023103003200620000_108.11.929.23","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081429"},{"key":"2023103003200620000_108.11.929.24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10897-018-0294-9","article-title":"Alone in a crowd? Parents of children with rare diseases\u2019 experiences of navigating the healthcare system","volume":"28","author":"Baumbusch","year":"2018","journal-title":"J Genet Couns"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2023-325762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T10:22:22Z","timestamp":1698661342000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2023-325762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,30]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/archdischild-2023-325762"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2023-325762","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}